Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

NCT01058616 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.

NCT NCT01058616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01058616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour
Lead sponsor
Lytix Biopharma AS
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
January 31, 2013
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer with transdermal accessible tumour